We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Silver Falcon | LSE:SILF | London | Ordinary Share | GB00BYX3WZ24 | ORD GBP0.01 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 3.75 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Apr 2019 to Apr 2024
TIDMSILF
RNS Number : 6971S
Silver Falcon PLC
04 October 2017
Silver Falcon Plc
("SILF" or "the Company")
Result of General Meeting
Silver Falcon Plc, (LSE: SILF), which has agreed to acquire the biotechnology company Hemogenyx Pharmaceuticals Limited ("Hemogenyx"), announces that following a General Meeting of the Company today all resolutions were duly approved by shareholders, including in relation to the waiver of Rule 9 of the Takeover Code and the Placing and Subscription.
Accordingly, the Acquisition and the related Placing and Subscription will complete tomorrow, 5 October 2017, subject only to the readmission of the enlarged share capital to the standard listing segment of the Official List and to trading on the main market for listed securities of the London Stock Exchange ("Admission"), which is expected to commence at 8.00 a.m. on 5 October 2017.
On Admission, the Company's total issued share capital will consist of 356,042,854 Ordinary Shares of GBP0.01 each. The Company holds no Ordinary Shares in treasury. The above figure (356,042,854) may be used by shareholders (and others with notification obligations) as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, Hemogenyx Pharmaceuticals plc under the FCA's Disclosure Guidance and Transparency Rules.
The Company will trade under the new company name of Hemogenyx Pharmaceuticals Plc and the Company's new London Stock Exchange TIDM ticker symbol will be HEMO and its ISIN will remain as GB00BYX3WZ24.
In addition, the Company's new website address will be www.hemogenyx.com
Enquiries:
Hot Features
Premium
Hemogenyx Pharmaceuticals Limited www.hemogenyx.com
Peter Redmond, Director Via Walbrook PR
Optiva Securities Ltd Tel: +44 (0)20 3137
1902
Christian Dennis
Shard Capital Partners LLP Tel: +44 (0)20 7186
9950
Damon Heath, Erik Woolgar
Peterhouse Corporate Finance Tel: +44 (0)20 7469
Limited 0930
Lucy Williams/Duncan Vasey
Walbrook PR Tel: +44 (0)20 7933 8780 or
hemogenyx@walbrookpr.com
Paul McManus Mob: +44 (0)7980 541 893
Flowcomms IR Mob: +44 (0)7891 627 441 or
sasha@flowcomms.com
Sasha Sethi
This information is provided by RNS
The company news service from the London Stock Exchange
END
ROMOKQDDKBDDPKK
(END) Dow Jones Newswires
October 04, 2017 06:16 ET (10:16 GMT)
1 Year Silver Falcon Chart |
1 Month Silver Falcon Chart |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
